T. Rowe Price Associates’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-29,597
| Closed | -$52K | – | 3136 |
|
|
2025
Q1 | $52K | Hold |
29,597
| – | – | ﹤0.01% | 2922 |
|
|
2024
Q4 | $47K | Sell |
29,597
-2,121,474
| -99% | -$3.26M | ﹤0.01% | 2953 |
|
|
2024
Q3 | $3.38M | Buy |
2,151,071
+2,130,678
| +10,448% | +$3.53M | ﹤0.01% | 1419 |
|
|
2024
Q2 | $0 | Buy |
+20,393
| New | +$47.3K | ﹤0.01% | 3012 |
|
|
2022
Q2 | – | Sell |
-18,460
| Closed | -$55K | – | 3009 |
|
|
2022
Q1 | $55K | Hold |
18,460
| – | – | ﹤0.01% | 2915 |
|
|
2021
Q4 | $58K | Buy |
18,460
+14,650
| +385% | +$65.1K | ﹤0.01% | 2920 |
|
|
2021
Q3 | $26K | Buy |
+3,810
| New | +$27.9K | ﹤0.01% | 2928 |
|
|
2017
Q1 | – | Sell |
-953
| Closed | -$257K | – | 2588 |
|
|
2016
Q4 | $257K | Hold |
953
| – | – | ﹤0.01% | 2302 |
|
|
2016
Q3 | $378K | Buy |
953
+73
| +8% | +$30K | ﹤0.01% | 2123 |
|
|
2016
Q2 | $305K | Sell |
880
-14
| -2% | -$10K | ﹤0.01% | 2161 |
|
|
2016
Q1 | $744K | Sell |
894
-150
| -14% | -$119K | ﹤0.01% | 1812 |
|
|
2015
Q4 | $1.09M | Buy |
1,044
+46
| +5% | +$46.1K | ﹤0.01% | 1668 |
|
|
2015
Q3 | $783K | Buy |
998
+15
| +2% | +$15.4K | ﹤0.01% | 1780 |
|
|
2015
Q2 | $1.29M | Buy |
983
+173
| +21% | +$279K | ﹤0.01% | 1673 |
|
|
2015
Q1 | $1.65M | Buy |
+810
| New | +$1.76M | ﹤0.01% | 1615 |
|
|
2014
Q4 | – | Sell |
-2,813
| Closed | -$2.31M | – | 2560 |
|
|
2014
Q3 | $2.31M | Buy |
2,813
+3
| +0.1% | +$2.54K | ﹤0.01% | 1556 |
|
|
2014
Q2 | $2.71M | Buy |
2,810
+5
| +0.2% | +$4.29K | ﹤0.01% | 1531 |
|
|
2014
Q1 | $3.04M | Sell |
2,805
-21
| -0.7% | -$23.3K | ﹤0.01% | 1495 |
|
|
2013
Q4 | $2.51M | Buy |
2,826
+604
| +27% | +$520K | ﹤0.01% | 1505 |
|
|
2013
Q3 | $2.51M | Buy |
+2,222
| New | +$2.62M | ﹤0.01% | 1512 |
|